Insmed eyes Arikayce label expansion on Phase IIIb lung disease success [Yahoo! Finance]
Insmed Incorporated (INSM)
Last insmed incorporated earnings: 4/30 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.insmed.com
Company Research
Source: Yahoo! Finance
In the ENCORE study (NCT04677569), the antibiotic plus a multidrug combination of azithromycin and ethambutol significantly improved the baseline change in respiratory symptom scores over the placebo-multidrug at month 13 – meeting the trial's primary endpoint. Alongside its impact on respiratory symptoms, Arikayce also triggered a culture conversion rate of 82.4% at 13 months, compared with 55.6% in the placebo arm. This means that significantly more patients given Arikayce over placebo tested negative for MAC bacteria following treatment. Arikayce's safety profile was generally consistent with previous studies of the drug, though 32% of patients did experience at least one severe treatment-emergent adverse event (TEAE) in the study. The TEAE-prompted discontinuation rate was 31% and 18% in the Arikayce and placebo treatment arms, respectively. The global ENCORE study enrolled 425 patients across 258 sites with MAC lung infections. None of the patients had previously received
Show less
Read more
Impact Snapshot
Event Time:
INSM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INSM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INSM alerts
High impacting Insmed Incorporated news events
Weekly update
A roundup of the hottest topics
INSM
News
- Insmed (INSM) had its price target raised by Stifel Nicolaus from $205.00 to $208.00. They now have a "buy" rating on the stock.MarketBeat
- Insmed (INSM) had its price target raised by Bank of America Corporation from $211.00 to $213.00. They now have a "buy" rating on the stock.MarketBeat
- A Look At Insmed (INSM) Valuation After Positive ENCORE Phase 3b ARIKAYCE Data [Yahoo! Finance]Yahoo! Finance
- Insmed CEO on its Arikayce drug after shares surge on trial results [CNBC]CNBC
- Insmed Incorporated (INSM) Shareholder/Analyst Call Transcript [Seeking Alpha]Seeking Alpha
INSM
Earnings
- 2/19/26 - Miss
INSM
Sec Filings
- 3/23/26 - Form 8-K
- 3/20/26 - Form 4
- 3/19/26 - Form 144
- INSM's page on the SEC website